Sorafenib (Nexavar®) is a multikinase inhibitor of VEGFR2-3, PDGFR, Raf kinase and c-Kit the receptor of stem cell factor, currently approved for the treatment of advanced HCC and renal cell carcinoma (RCC) [5,80]. This evidence concerns the gene KIT and renal cell carcinoma.